Europe's Seed Rounds Got Bigger and Cheaper. Its Series C Quadrupled.

What's New

European founders are raising larger rounds at lower prices, and their American counterparts are doing precisely the reverse. Median European deal value rose 25% year on year to EUR 2.5 million while the median European pre money valuation fell 5.4% to EUR 7.5 million, against US deal sizes down 13.5% and US valuations up 45%, according to PitchBook's Q2 2026 European VC Valuations Report, published August 20. That divergence repeats inside Europe itself. Pre seed and seed valuations fell 4.7% to EUR 4.8 million, the only stage to decline, while Series C to D valuations rose 306.8% to EUR 897.9 million and Series E and beyond rose 115.3%. The single European median masks two markets moving in opposite directions.

Why It Matters

A funnel where entry valuations compress while late stage valuations quadruple produces enormous dilution asymmetry between early and late investors in the same company. For LPs, that changes which vintage and which stage actually captures European AI value, and the answer increasingly is neither the seed fund nor the buyer at EUR 900 million. For GPs, the practical consequence is that European seed remains the cheapest entry point in developed markets while the exit path for those positions runs through a late stage market priced on a handful of names. For platforms, the monitoring problem is that a single European portfolio now spans two valuation regimes that share no logic.

Big Picture Drivers

• The top and bottom of the funnel have decoupled: Series E and beyond valuations rose 115.3% to EUR 3.07 billion while pre seed and seed was the only stage to record a decline.

• AI concentration explains the top: Eight of the top ten unicorn deals in Q2 were AI companies, led by Wayve, ICEYE and Ineffable Intelligence, and half the eight new unicorns minted in the quarter were AI related.

• Core regions are repricing downward: France and Benelux pre seed valuations fell 37.6% to EUR 3.2 million and the UK and Ireland fell to EUR 4.6 million, below the European benchmark, even as deal sizes rose in both.

• Down rounds hit an all time low, but unevenly: European down rounds fell to 11.8% of total rounds, still above the 8.4% US level, with healthtech at 20.4% and fintech at 14.6% carrying the damage.

• Nontraditional investors are paying up hardest: Median valuations for rounds involving private equity investors doubled to EUR 31.5 million, and asset managers and sovereign funds also moved sharply.

• Mobile overtook AI at Series A to B: The mobile vertical's median valuation reached EUR 78.6 million, up 81.5%, against EUR 55.2 million for AI, which suggests the AI premium has stopped being automatic at that stage.

By The Numbers

• EUR 609.1 billion in aggregate European unicorn value, across 175 names, with 18 minted so far in 2026.

• EUR 15.5 billion of unicorn deal value in the first half, against EUR 17.8 billion for all of 2025, on 47 transactions.

• EUR 58.4 million median exit valuation, an all time high, against a previous peak of EUR 33.6 million in 2021 and EUR 23.3 million last year.

• EUR 53.8 million median buyout exit, down 29.5%, the one exit route moving backwards while acquisitions and listings rose.

• EUR 127.8 billion across 174 soonicorns, of which 16 sit above EUR 900 million, giving Europe a visible pipeline into the unicorn herd.

• 16.6x valuation step up for Fractile, the largest in the quarter, illustrating how much of the aggregate move rests on individual repricings.

Key Trends to Watch

• The IPO window is open but not for venture: European listings have been driven by companies that never took venture backing, so favourable listing valuations have not yet translated into venture liquidity.

• Series C valuations may taper as data fills in: PitchBook flags that the EUR 897.9 million median rests on a thin set of disclosed rounds and could fall as more of the year is captured.

• The soonicorn pipeline decides 2027: With 174 names between EUR 500 million and EUR 1 billion and unicorn exits still tepid, the herd will keep accumulating value rather than releasing it.

• Healthtech is where the correction is actually happening: A 20.4% down round rate against 11.4% for SaaS marks the sector out as the one taking real valuation pain.

• Regional dispersion is widening: Southern Europe posted the largest Series A to B deal size gain at 48.1% while DACH declined 6%, which breaks the habit of treating European venture as one market.

The Wrap

Europe now has two venture markets operating under one label. One is an early stage market where valuations are falling in the largest ecosystems and founders are compensating by raising more money at flat or lower prices. The other is a late stage AI market priced against US comparables and detached from anything below it. That divergence is workable while capital keeps arriving at the top, and it becomes a serious problem the moment it does not, because the middle of the funnel has no independent pricing anchor. For technology providers, the requirement is a valuation layer that can hold both regimes at once, since a European fund's marks now depend more on which stage it entered than on which company it picked.